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Abstract
The commonest medical conditions following menopause are osteoporosis and atherosclerotic
disease. This review considers the safety of pharmacotherapy of osteoporosis in cardiology
patients. Drugs used for osteoporosis treatment may have adverse effects on the cardiovascular
system. This article has detailed analysed of current drug classes, such as the bisphosphonates
and strontium ranelate, as well as reviewed of the controversy surrounding hormone replace-
ment therapy (HRT) and the selective estrogen receptor modulators (SERMs). Additionally, we
discuss the adverse effects on the heart of calcium and drugs influencing calcium metabolism
such as vitamin D, parathormone and calcitonin. We look at the interference between oste-
oporosis treatment and the drugs used for atherosclerosis. Moreover, the side effects on bones of
cardiology drugs are analysed. Lastly, the possible advantages of selected drugs used for car-
diovascular diseases in terms of osteoporosis prevention are evaluated. (Cardiol J 2010; 17, 4:
335–343)
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Introduction
Osteoporosis is a disease in which bones be-
come fragile and more likely to break. If not pre-
vented, or if left untreated, osteoporosis can
progress painlessly until a bone breaks. These bro-
ken bones, also known as fractures, occur typically
in the hip, spine, and wrist. Anyone can develop
osteoporosis, but it is commonest in older women.
Risk factors include: getting older, having osteope-
nia (low bone mass), being small and thin, having
a family history of osteoporosis, being a white or
Asian woman and taking certain medicines. Especial-
ly this last named concerns patients suffering from
cardiac diseases. Drugs used for osteoporosis treat-
ment may have adverse effects on the cardiovascu-
lar system. On the other hand, some cardiology drugs
can provoke osteoporosis. Other cardiological treat-
ment may prevent the loss of bone mass.
Cardiovascular side effects
of drugs for osteoporosis
Bisphosphonate
An article and accompanying letter to the edi-
tor of The New England Journal of Medicine [1, 2]
describe increased rates of serious atrial fibrillation
(AF) (defined by the authors as life-threatening or
resulting in hospitalization or disability) in two dif-
ferent studies of older women with osteoporosis
treated with the bisphosphonates, zoledronic acid
and alendronate. In both studies, more women who
received one of the bisphosphonates (zoledronic
acid: 1.3% or alendronate: 1.5%) reportedly deve-
loped serious AF as compared to women who re-
ceived a placebo (zoledronic acid study: 0.5%, al-
endronate study: 1.0%). In both studies, the rates
of all AF (serious plus non-serious) were not sig-
nificantly different between groups treated with
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bisphosphonate versus placebo. These two research
reports suggest a possible link between two bone-
building drugs and irregular heart rhythms. The
signs of a heart problem were more pronounced
with zoledronic acid, a drug given as a once-a-year,
15-minute intravenous infusion. But there was
a hint of similar trouble in a few women who took
the leading osteoporosis pill with alendronate.
There appeared to be a 50 per cent greater risk of
serious heart rhythm in women who took the daily pill
than among those who did not. About half of the 6,459
women took zoledronic acid, and 47 developed AF,
compared with just 31 cases among the other women.
Black et al. [1] report a significant increase in
the risk of serious AF adverse events (defined as
events resulting in hospitalization or disability or
judged to be life-threatening) associated with once-
-yearly infusions of intravenous zoledronic acid for
the treatment of osteoporosis in post-menopausal
women. However, there was no increased risk of all
adverse events of AF with such infusions.
The Food and Drugs Administration (FDA),
after reviewing data concerning treatment with bis-
phosphonates, announced in 2007 that there is po-
tential increased risk for AF in patients with os-
teoporosis treated with these drugs [3]. That review
involved the following bisphosphonates: alendro-
nate, ibandronate, risedronate and zoledronic acid.
In a report published in November 2008, an update
to the previous communication, the FDA stated that
across all studies, no clear association between
overall bisphosphonate exposure and the rate of
serious or nonserious AF was observed. Even in-
creasing the dosage and duration of treatment was
not associated with an increased rate of arrhythmia
onset [4]. The FDA update concluded that, based
on the information currently available, physicians
should not alter their prescribing patterns for bis-
phosphonates and patients should not stop taking
these drugs.
The bisphosphonates have also potentially pro-
tective effects on atherosclerosis. The study by
Price et al. [5] in rats showed that the amino bis-
phosphonates alendronate and ibandronate inhibit
warfarin-induced artery calcification, which is a sign
of atherosclerosis.
Strontium ranelate
Strontium ranelate is composed of two atoms
of stable strontium (an element with properties simi-
lar to calcium) and one molecule of ranelic acid.
Strontium incorporates within bone mineral by sub-
stituting for calcium ions and has also been found
to stimulate alkaline phosphatase activity, which
differentiates it from other drugs used in the treat-
ment of osteoporosis. It is thought to have a dual
effect on bone metabolism, increasing bone forma-
tion and decreasing bone resorption [6]. It is li-
censed for the treatment of post-menopausal os-
teoporosis to reduce the risk of vertebral and hip
fractures. Strontium ranelate is not recommended
in patients with severe renal impairment and should
be used with caution in patients at increased risk of
venous thromboembolism (VTE) [6]. In phase III
studies, the annual incidence of VTE observed over
four years was approximately 0.7%, with a relative
risk of 1.42 (p = 0.036) in strontium ranelate-trea-
ted patients, as compared to placebo-treated patients.
The cause of these findings is unknown. The risk for
strontium ranelate appears to be less than that seen
with Selective Estrogen Receptor Modulator
(SERM) and hormone replacement therapy (HRT)
[7]. The study by Halil et al. [8] demonstrated that
after 60 days of treatment with strontium ranelate,
there was no statistically significant prolongation in
PFA-100 in vitro bleeding time and no statistically
significant change in the critical hemostatic para-
meters in patients receiving strontium ranelate that
led to discontinuation of the treatment. None of the
subjects developed clinical VTE during the two
month period of strontium ranelate treatment.
Hormone replacement therapy
Estrogen depletion has one of the most pro-
found effects on skeletal physiology in both humans
and non-human primates. A potential role for es-
trogen in cardiovascular disease (CVD) protection
has been long suggested by the observation that
women have a reduced relative CVD risk as com-
pared to men, but that this benefit is lost after meno-
pause, when circulating estrogen levels decrease
dramatically [9]. The mechanisms by which estro-
gen may protect against heart disease include en-
dothelial-mediated vascular effects, non-endothe-
lial vascular effects, favorable lipoprotein effects,
possible favorable effects on glucose and insulin
homeostasis, changes in extracellular matrix and
plaque stabilization, and facilitation of collateral
vessel formation [10].
Until recently, HRT has been the standard
treatment for osteoporosis based on the fact that
sex steroids play a critical role in bone homeosta-
sis. Both estrogens and androgens suppress bone
remodeling by decreasing the number of resorption/
/formation cycles [11].
Unfortunately, the estrogen/medroxyproges-
terone arm of the Women’s Health Initiative (WHI)
337
Tomasz Zapolski, Andrzej Wysokiński, Safety of pharmacotherapy of osteoporosis in cardiology patients
www.cardiologyjournal.org
study was terminated prematurely because of an
increased risk of CVD events [12]. Two secondary
prevention trials of HRT and heart disease (in pa-
tients with evidence of already established athero-
sclerosis), the HERS (Heart and Estrogen/Proges-
tin Replacement Study) [13] and ERA (Estrogen
Replacement and Atherosclerosis) study [14],
showed no reduction in heart disease or regression
of atherosclerotic plaque in users of HRT or ERT.
Currently, HRT cannot be advocated for treatment
or prevention of coronary artery disease.
The relationship between HRT and stroke re-
mains uncertain. HERS and WEST (Women’s Es-
trogen for Stroke Trial) studies showed that HRT
was not significantly related to transient strokes or
ischemic attacks [13, 15]. The WHI trial reported
an increased risk of stroke. An analysis of 18 ob-
servational studies going back to 1980 concluded
that HRT has a neutral effect on stroke [16].
Oral HRT causes a small but significant in-
crease in venous thrombosis and pulmonary embo-
lism. HRT doubles the risk of venous thromboem-
bolism (VTE), with the highest risk occurring in the
first year of use [17]. Advancing age, obesity and
an underlying thrombophilia such as Factor V
Leiden significantly increase risk. In WHI, the num-
ber of cases of VTE in placebo users per 1,000 women
per year at 50–59 years was 0.8, at 60–69 years
1.9, and at 70–79 years 2.7 [17]. Randomized trial
data strongly suggests that women who have pre-
viously suffered a VTE have an increased risk of
recurrence in the first year of HRT use [18]. Thus
previous history of VTE contraindicates oral HRT.
Transdermal HRT may be associated with a lower
risk [17].
Selective estrogen receptor modulators
The biological actions of estrogen are largely
mediated by two distinct estrogen receptor iso-
forms, namely ERalpha and ERbeta, that are widely
distributed in tissues including the cardiovascular
system. Selective estrogen receptor modulators
(SERMs) are a group of agents being studied for
their breast cancer risk reduction effects. SERMs
are non-steroidal compounds that elicit estrogen
agonist effects in some tissues, such as bone, and
estrogen antagonist effects in others, such as breast,
through specific, high-affinity binding to the estro-
gen receptor. SERMs act by interacting with ER,
but differ from estrogens by eliciting agonist or an-
tagonist effects depending on the target tissue [20].
Tissue-selective SERMs may be safer agents than
endogenous estrogens for cardiovascular disease.
The most representative compound of this class is
raloxifene, approved for osteoporosis as well as
breast cancer treatment.
Raloxifene, a benzothiophene SERM that is
chemically distinct from estradiol, is approved for
the treatment and prevention of osteoporosis in
post-menopausal women [21]. The most serious
adverse effect associated with raloxifene is the ap-
proximately tripled risk of VTE [6]. Raloxifene is
associated with an increased risk of venous throm-
boembolic events, particularly during the first
four months of treatment, which is similar to the
reported risk associated with hormone replacement
therapy. The impact of raloxifene on cardiovascu-
lar disease is unclear, although there is evidence
that it lowers fibrinogen and both total and low-den-
sity lipoprotein (LDL) cholesterol levels without
increasing high-density lipoprotein (HDL) choles-
terol [6]. Raloxifene mediates acute ER- and endo-
thelium-dependent vasorelaxation in rabbit coronary
arteries due to stimulation of eNOS expression [22].
Similar to estrogen, raloxifene has antiproliferative
properties in vascular smooth muscle cells [23]. The
MORE trial was an osteoporosis treatment trial
conducted in post-menopausal women, with breast
cancer risk reduction as a secondary objective [24].
Raloxifene is currently being studied for breast can-
cer risk reduction effects in the Continuing Out-
comes Relevant to Evista® (CORE), Raloxifene Use
for The Heart (RUTH), and Study of Tamoxifen and
Raloxifene (STAR) clinical trials. The RUTH par-
ticipants were selected based on the presence of
documented coronary heart disease (50%) or mul-
tiple risk factors increasing their risk for a coronary
heart disease event (50%) [25]. After an average of
five years, the RUTH study showed that deaths and
major heart problems were about the same in both
the group receiving raloxifene and the one taking
a placebo. Raloxifene users experienced one-third
fewer cases of breast cancer and about half the num-
ber of invasive breast cancers [26]. Raloxifene is
contraindicated in people with a history of venous
thromboembolism (VTE), hepatic impairment,
cholestasis, severe renal impairment, undiagnosed
uterine bleeding, and endometrial cancer [6].
Besides raloxifene, there are several other
SERMs such as: tamoxifene, toremifene, and ful-
vestrant; all are approved for breast cancer, and clo-
miphene is used for ovulatory dysfunction.
Toremifene is potentially dangerous for cardiac
patients. Toremifene is associated with a dose-de-
pendent increase in QT interval, which carries a risk
of serious cardiac arrhythmia [27]. Therefore
EMEA [28] stated that toremifene must not be used
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in patients with QT prolongation and also heart fail-
ure or a history of symptomatic arrhythmias. An
additive effect on QT interval prolongation between
toremifene and antiarrhythmic drugs class IA (qui-
nidine, hydroquinidine, disopyramide) and class III
(amiodarone, dronedarone, sotalol, dofetilide, ibutil-
ide) cannot be excluded. Therefore co-administration
of toremifene and the mentioned medications is con-
traindicated. There is some data indicating that an-
other drug from the SERMs group, tamoxifene, is
an agent that prolongs the QT interval and/or in some
reports has been associated with torsades de pointes,
but at this time there is a lack of substantial evidence
for causing torsades de pointes [29].
Calcium and vitamin D supplements are gen-
erally used as an adjunct to other treatments in the
management of patients with osteoporosis, based
on the fact that virtually all large scale randomized
controlled trials of anti-osteoporotic therapies have
included calcium and vitamin D supplements as part
of the treatment regimen. Calcium and vitamin D
supplements do not appear to be effective in pre-
venting fractures when used alone, except in pa-
tients at high risk of calcium and vitamin D deficiency
such as the housebound elderly, or institutionalized
individuals [30].
Side effects from a reasonable dose of calcium
(1,000 mg/day) are very low and usually don’t affect
the cardiovascular system. Increased dietary calcium
intake may slightly decrease blood pressure [31].
Taking calcium with a b-blocker (such as
atenolol) may interfere with blood levels of both the
calcium and the b-blocker [32]. Study results are
conflicting, however. Similarly, it has been reported
that calcium may reverse the therapeutic effects as
well as the side effects of calcium channel blockers
(such as verapamil) often prescribed for the treat-
ment of high blood pressure [33]. These study
results are also controversial. People taking vera-
pamil or another calcium channel blocker along with
calcium supplements should probably have their
blood pressure checked regularly. A class of medi-
cations known as bile acid sequestrants (including
cholestyramine, colestipol, and colesevelam), used
to treat high cholesterol, may interfere with nor-
mal calcium absorption and increase the loss of cal-
cium in the urine [34]. Supplementation, therefore,
with calcium and vitamin D may be recommended
by healthcare provider. High levels of calcium may
increase the likelihood of a toxic reaction to digo-
xin, a medication used to treat irregular heart
rhythms [35]. On the other hand, low levels of cal-
cium cause this medication to be ineffective. People
who are taking digoxin should have blood calcium
levels monitored closely. Two different classes of
diuretics interact with calcium in opposite ways:
thiazide diuretics such as hydrochlorothiazide can
raise calcium levels in the blood, while loop diure-
tics, such as furosemide and bumetanide, can de-
crease calcium levels [36].
Vitamin D promotes the absorption of calcium
and phosphorus. It regulates how much calcium
remains in blood and how much is deposited in
bones and teeth. This high prevalence of hypovita-
minosis D might contribute to osteoporosis. Insuf-
ficient vitamin D levels have been linked to heart
failure [37]. Studies have already shown that vita-
min D can lower inflammation by increasing levels
of anti-inflammatory messengers like the cytokine
named IL-10 (interleukin-10) [38]. A 2006 analysis
of vitamin D metabolism  suggested that vitamin D
may be directly involved in cholesterol reduction
[39]. Adequate vitamin D levels may be important
for decreasing the risk of high blood pressure [40].
But lastly, a completed study by Hsia et al. [41] has
shown that calcium/vitamin D supplementation
neither increased nor decreased coronary or cere-
brovascular risk in generally healthy post-meno-
pausal women over a seven-year use period. Excess
vitamin D, on the other hand, can accelerate bone
resorption and also some cardiac side effects. The
symptoms of vitamin D toxicity are a result of hy-
percalcemia (an elevated level of calcium in the
blood) caused by increased intestinal calcium ab-
sorption. In humans, manifestations of vitamin D
toxicity include hypercalcemia, hypercalciuria, nau-
sea, anorexia, lethargy, mental disturbances, ectop-
ic soft tissue calcification, including vascular calci-
fication and nephrocalcinosis, and renal failure. The
induction of hypercalcemia by toxic levels of vita-
min D may precipitate cardiac arrhythmia in pa-
tients on digitalis [42]. Rajasree et al. [43] showed
elevated risk of ischemic heart disease when 25hy-
droxyvitamin D3 (25D3) was above 89 ng/mL. In an
animal study [44], the amino bisphosphonate iban-
dronate prevents vitamin D toxicity and inhibits
vitamin D-induced calcification of arteries, cartilage,
lungs and kidneys. The following medications, used
by cardiology patients, should not be taken at the
same time as vitamin D because they can decrease
the intestinal absorption of vitamin D:
cholestyramine, colestipol, orlistat, mineral oil, and
the fat substitute Olestra.
Parathormone (PTH). Parathyroid hormone
is the most important endocrine regulator of calcium
and phosphorus concentration in extracellular
fluid. This hormone is secreted from cells of the par-
athyroid glands and finds its major target cells in
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bone and kidney. Another hormone, parathyroid
hormone-related protein, binds to the same recep-
tor as parathyroid hormone and has major effects
on development. The influence of parathyroid hor-
mone on the cardiovascular system is unclear. Data
collected on uremic rats indicates that heart cell is
a target organ for PTH and may have receptors for
the hormone; PTH increases beating rate of heart
cells and causes early death of cells; PTH effect
appears to be due to calcium entry into heart cells;
the locus of action through which PTH induces cal-
cium entry is different from that for catecholamines;
and uremic serum has no effect unless it contains
PTH. Data suggests that myocardial damage may
occur in uremia due to prolonged exposure to very
high blood levels of PTH, and assign new dimen-
sions to PTH toxicity in uremia [45]. A study by
Ogino et al. [46] suggests that the physiologically
important functions of parathyroid hormone-related
protein are chronothropy and vascular dilatation
rather than inotropy.
Teriparatide is a recombinant form of parathy-
roid hormone, used in the treatment of advanced
osteoporosis. Teriparatide can possibly influence
the heart by changing calcium metabolism and in
that way interfere with cardiac drugs. The study by
Benson et al. [47] showed that teriparatide, 20 mg
subcutaneously, does not alter the cardiac effect of
digitalis. The assessment of effects of an acute dose
of teriparatide on blood pressure and heart rate
(pulse rate) showed that teriparatide was safe and
well tolerated in subjects with mild or moderate
heart failure. The drug was not associated with
changes in supine or standing hemodynamic para-
meters, QT or other ECG abnormalities. In an open-
-label, non-randomized study performed in 14 women
with hypertension, teriparatide 40 mg was admi-
nistered alone and in combination with atenolol or
with a long-acting calcium channel antagonist. Re-
sults showed an increase in peak pulse rate and de-
crease in nadir blood pressure. Neither calcium
channel antagonists nor atenolol potentiate the
blood response associated with teriparatide. In
a single blind, randomized, two-period crossover
study, the effects of a 20 mg subcutaneous dose of
teriparatide on cardiac conduction and re-polariza-
tion were evaluated. Results showed that teriparati-
de was associated with a small but statistically sig-
nificant decrease in average standing SBP compared
to placebo, a slight increase in average pulse rate,
relative to placebo, but approximately three and two
beats per minute in the standing and supine posi-
tions, respectively and small, statistically significant
decreases in RR and QT intervals, but no changes
in PR and QRS.
A global analysis of ECG data obtained from
five clinical studies of 118 subjects has been per-
formed. The results did not show apparent adverse
effects on ECG intervals with single subcutaneous
doses of teriparatide in amounts of 20, 40 and 80 mg.
No effect on the PR and QRS intervals was ob-
served; however, dose-related shortenings in the
RR, QT and QTc intervals were observed. A mo-
dest and not significant increase in heart rate was
also observed [48].
Calcitonin is an osteoclast inhibitor which is
effective in preventing post-menopausal bone loss
and the secondary prevention of vertebral fractures
in post-menopausal osteoporosis. Synthetic salmon
calcitonin has the same effects as the natural human
hormone and is used to prevent bone breakdown.
There is no evidence that calcitonin causes severe
side effects on the cardiovascular system. Very rare
reactions such as elevation of blood pressure or ta-
chycardia, hypotonia and collapse have been ob-
served due to anaphylactic-type reactions [49].
The influence of cardiologic
pharmacotherapy on osteoporosis
Heparin
Osteoporosis is a well-recognized complication
of long-term heparin therapy [50, 51]. About one
third of patients have subclinical reductions in bone
density, but only 2% to 3% of those receiving pro-
tracted heparin therapy develop symptomatic frac-
tures [52, 53].
In heparin-treated rats, histomorphometric
analysis of the distal third of femurs demonstrated
a significant loss of cancellous bone accompanied
by increased numbers of osteoclasts, and decreased
numbers of osteoblasts, lining the trabecular bone
surface. Biochemical markers of bone turnover sup-
ported these findings. This suggests  that heparin
causes bone loss not only by increasing osteoclas-
tic bone resorption, but also by decreasing osteo-
blastic bone formation [54, 55]. Treatment was as-
sociated with a 45% decrease in the number of os-
teoblasts and an 81% decrease in the amount of
unmineralized collagen (osteoid) lining the cancel-
lous bone surface. Furthermore, heparin increased
osteoclast surface by 58%, indicating that heparin
causes bone loss both by decreasing the rate of bone
formation and by increasing bone resorption [54].
A study performed in rats by Shaughnessy et
al. [56] suggests that heparin-induced osteoporosis
is not rapidly reversible because heparin is seques-
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tered in bone for an extended period. Heparin causes
cancellous bone loss by influencing bone remode-
ling rather than growth. Similarly in humans, he-
parin-induced reduction in bone density is not rap-
idly reversible. In 61 pre-menopausal women treat-
ed with long-term heparin therapy, compared to
age-matched controls, there were no significant
differences in mean radial and spinal bone densities,
but a significantly greater proportion of women who
had received heparin two years previously had bone
densities below a predefined minimal level [57].
Sequestration of heparin in bone provides a plausi-
ble explanation for these results.
The site of heparin sequestration in bone is
unknown. Heparin has been reported to bind to
endothelial cells and macrophages, as well as to
a variety of plasma proteins. The sequestration of
heparin within the bone microenvironment may
explain the lack of recovery of bone loss over the
28-day study period after heparin therapy was
stopped [56]. Such binding can also explain heparin’s
poor bioavailability at low doses and the variable
anticoagulant response that it produces when used
therapeutically [58].
Low molecular weight heparin
Low molecular weight heparin (LMWH) may
carry a lower risk of osteoporosis than unfraction-
ated heparin (UFH). Dalteparin, 5,000 anti-Xa U sc,
was compared with UFH, 10,000 U sc bid, for three
to six months in 80 patients with deep vein throm-
bosis. Six of the 40 patients who received UFH de-
veloped spinal fractures, compared to one patient
receiving dalteparin [59]. Some data indicates
a dose-dependent decrease in cancellous bone vol-
ume. In rats treated with UFH or the LMWH tin-
zaparin (0.5 to 1.0 mg) for 32 days, UFH caused sig-
nificantly greater cancellous bone loss than LMWH
[55]. Although UFH and LMWH decreased osteo-
blast and osteoid surface similarly, only UFH in-
creased osteoclast surface. Both UFH and LMWH
reduced serum alkaline phosphatase, consistent
with reduced bone formation, while there is a tran-
sient increase in urinary type 1 collagen cross-
linked pyridinoline, consistent with an increase in
bone resorption. Whereas UFH decreases cancel-
lous bone volume both by decreasing the rate of
bone formation and increasing the rate of bone re-
sorption, LMWH causes less osteopenia, decreas-
ing only the rate of bone formation [8]. Unlike hep-
arin, only > 50-fold higher concentrations of the
LMWH preparations enoxaparin, dalteparin, tinza-
parin, and ardeparin than used clinically were need-
ed to stimulate bone resorption at concentrations
usually used for prophylaxis and treatment of the
thromboembolism [60]. Another LMWH,  fonda-
parinux, does not appear to have a negative effect
on bone metabolism. Therefore, fondaparinux may
be a safe and effective alternative to UFH and
LMWH in women who require anticoagulation dur-
ing pregnancy [61].
Warfarin
Vitamin K is an essential factor for the synthe-
sis of plasma-clotting proteins. Because g-carboxy-
lation of specific glutamic acid residues is also re-
quired for activation of osteocalcin and other bone
matrix proteins [62], vitamin K antagonists might
increase the risk of osteoporotic fractures. There
are two mechanisms by which warfarin use could
predispose to osteoporotic fractures: directly, by
g-carboxylation in osteocalcin and other bone ma-
trix proteins; and indirectly, because patients tak-
ing warfarin may limit their dietary intake of foods
rich in vitamin K. In utero, vitamin K antagonists
interfere with bone formation. During the first tri-
mester, exposure to warfarin causes embryopathy
that includes nasal hypoplasia and epiphyses stip-
pling [63]. Children who receive long-term vitamin
K antagonist therapy have reduced bone density
[64]. A low vitamin K concentration is associated
with reduced bone mineral density (BMD) [65].
Clinical trials support the role of vitamin K in main-
taining bone health. In randomized, controlled tri-
als of osteoporotic women, participants randomized
to receive vitamin K2 (menatetrenone, 45 mg/day)
had slower loss of bone mineral density and a re-
duced risk of subsequent osteoporotic fractures than
control women [66, 67].
Warfarin is the vitamin K antagonist, pre-
scribed to millions of people worldwide to decrease
their risk of clotting. In a retrospective study of
14,564 patients with AF, long-term use of warfarin
was associated with a 25% increased risk of os-
teoporotic fracture [68]. In contrast, use of warfarin
for less than one year had no significant association
with osteoporotic fracture. Among those with long-
-term use, warfarin was most strongly associated
with vertebral fractures. Carabello et al. [69] has
found that long-term exposure to oral anticoagula-
tion is associated with an increased risk of verte-
bral and rib fractures.
Clinicians should carefully assess anticoagula-
ted patients for osteoporosis risk, monitor BMD,
and refer them to dietitians for dietary and supple-
ment advice on bone health. Epidemiological stu-
dies and clinical trials consistently indicate that
vitamin K has a positive effect on bone mineral
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density and decreases fracture risk. Typical dietary
intakes of vitamin K are below the levels associ-
ated with better BMD and reduced fracture risk;
thus issues of increasing dietary intakes, supple-
mentation, and/or fortification arise. Anticoagu-
lants that do not affect vitamin K metabolism are
now available and make clinical trials feasible to
address the question of whether coumarins ad-
versely affect bone [70].
Acenocumarol
The study by Wawrzyńska et al. [71] has shown
a distinct and progressive decrease in BMD in pa-
tients on prolonged anticoagulation with the Vitamin K
antagonist acenocumarol. They also compared oral
anticoagulants to LMWH and found that BMD is
more evident in patients on LMWH therapy.
When prescribing Vitamin K antagonists, es-
pecially to elderly patients at high risk of falling,
physicians should instruct them to have adequate
intake of calcium and vitamin D, exercise regular-
ly, wear stable shoes, use walking aids, and discon-
tinue unnecessary medications.
Beta-blockers
Beta-adrenergic antagonists have a protective
effect on bone density and risk of fracture. Gage et
al. [68] found that patients prescribed b-adrenergic
antagonists had a 16% reduction in subsequent os-
teoporotic fracture. The association between hyper-
thyroidism and osteoporotic fractures suggests that
part of the possible benefit of b-adrenergic antago-
nists could be mediated via the known inhibition of
thyroxine [72].
Thiazide diuretics
Thiazide diuretics are often used to treat high
blood pressure, but they may also protect against
age-related bone loss by reducing the amount of
calcium expelled in urine. A study performed by
Schoofs et al. [73] has shown that people aged over
55 who took thiazide diuretics for a year or more
had about a 50% lower risk of suffering a potential-
ly debilitating hip fracture than those who never
took diuretics. This protective effect disappears
within four months after use is discontinued.
Calcium channel blockers
Calcium channel blockers are an important
group of vasodilators in the treatment of hyperten-
sion and coronary artery disease. There is no evi-
dence that calcium channel blockers cause os-
teoporosis. It affects the calcium channels in the
muscles not the levels of calcium in blood.
Statins
Low bone mineral density has also been asso-
ciated with vascular diseases or atherosclerosis.
Observational studies found that the risk of frac-
tures was approximately half as high in people tak-
ing statins as in nonusers [74]. At the same time,
people taking non-statin lipid-lowering drugs had
approximately the same risk as nonusers. On the
other hand, LaCroix et al. [75], analyzing data from
more than 90,000 post-menopausal women, found
no link between statin use and risk of hip fractures.
However, few women in this study had used statins
for more than three years. Therefore, the findings
do not rule out the possibility that long-term statin
use might reduce fracture risk.
Statins appear to enhance osteoblastic activity
by both increasing expression of bone morphoge-
netic protein-2, a stimulator of osteoblast differen-
tiation, and diminishing osteoclast activity by pre-
venting prenylation and activation of key intrace-
llular proteins [76]. The mechanism of this effect
is unclear because it is impossible to separate anti-
resorptive and anabolic effects in vitro.
Currently available statins, which are designed
for lipid-lowering, may be suboptimal for treating
osteoporosis; however, insights from studies may
lead to development of similar molecules that more
effectively promote bone formation and inhibit re-
sorption [76].
Closing remarks
Most drugs used for the treatment of os-
teoporosis are safe for cardiology patients. Bispho-
sphonates can rarely provoke events of AF. Stron-
tium ranelate is not recommended in patients with
severe renal impairment and should be used with
caution in patients at increased risk of VTEs.
Hormone replacement therapy has not been
proven to be beneficial in primary and secondary
prevention of coronary heart disease; in fact, it may
result in a slightly increased rate of CHD. HRT
should not be initiated for women with existing
heart disease. HRT increases in thromboembolic
events mainly in the first year of use. The relation-
ship between HRT and stroke remains uncertain.
HRT initiation and continuation should be based on:
established non-coronary benefits and risks, possi-
ble coronary benefits and risks, patient preference.
Treatment with raloxifene was associated with:
increased risk of VTEs, no effect on all-cause mor-
tality, no effect on all strokes, increased risk of
death due to stroke. The risk-benefit balance should
be considered in women at risk for stroke. Based
on the RUTH trial, raloxifene should not be used
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for the primary or secondary prevention of cardio-
vascular disease.
Vitamine D, parathormone and calcitonin influ-
ence calcium metabolism, and thus may lead to car-
diac rhythm disturbances as well as interfere with
some cardiological drugs.
Cardiology drugs such as statins, b-adrenergic
antagonists and thiazides may provide an added
benefit to the treatment of osteoporosis, a common
disorder, implying a significant public health bene-
fit, while significantly reducing cardiovascular
events.
Unfortunately, long-term heparin therapy can
cause osteoporosis. LMWHs may carry a lower risk
of osteoporosis than UFH. Osteoporosis is a well-
recognized complication of treatment with the vi-
tamin K antagonist such as warfarin and acenocu-
marol. Clinicians should carefully assess anticoa-
gulated patients for osteoporosis risk, refer them to
dietitians for dietary and supplement advice on bone
health, and instruct them to discontinue unneces-
sary medications.
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